GlycoMimetics (GLYC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH
November 6, 2019 10:04 AM ESTGlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the companys research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando.
Of particular note, clinical data from the Companys recent Phase 1/2 study of uproleselan, an E-selectin antagonist and the companys lead wholly owned clinical candidate, were selected for a poster presentation on Sunday, December 8 during a session on biology of AML. The presentation will feature data showing uproleselans ability... More
